{"id":1013885,"date":"2026-10-27T07:06:02","date_gmt":"2026-10-27T11:06:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/"},"modified":"2026-10-27T07:06:02","modified_gmt":"2026-10-27T11:06:02","slug":"iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/","title":{"rendered":"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PHILADELPHIA, Oct.  27, 2026  (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates.<\/p>\n<p align=\"left\">To listen to the live or archived audio webcast, please register at <a href=\"https:\/\/edge.media-server.com\/mmc\/p\/j9pwh6ke\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/edge.media-server.com\/mmc\/p\/j9pwh6ke<\/u><\/a>. The live and archived webcast can be accessed in the Investors section of the Company\u2019s website, <a href=\"https:\/\/ir.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">IR.Iovance.com<\/a>. The archived webcast will be available for one year.\u00a0<\/p>\n<p>\n        <strong>About\u00a0Iovance Biotherapeutics, Inc.<\/strong>\u00a0<\/p>\n<p align=\"left\">Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi<sup>\u00ae <\/sup>(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The\u00a0<a href=\"https:\/\/www.iovance.com\/our-science\/til-platform\/\" rel=\"nofollow\" target=\"_blank\">Iovance TIL platform<\/a>\u00a0spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world.\u00a0For more information, please visit\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>Amtagvi<sup>\u00ae<\/sup> and its accompanying design marks, Proleukin<sup>\u00ae<\/sup>, Iovance<sup>\u00ae<\/sup>, and IovanceCares\u2122\u00a0are trademarks and registered trademarks of\u00a0Iovance Biotherapeutics, Inc.\u00a0or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.<\/p>\n<p>Information on Iovance\u2019s broad, industry-leading patent portfolio is available on the Intellectual Property page on\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain matters discussed in this press release are \u201cforward-looking statements\u201d of Iovance Biotherapeutics, Inc. (hereinafter referred to as the \u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Without limiting the foregoing, we may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cachievable,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>IR@iovance.com<br \/>650-260-7120\u00a0ext. 150<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>PR@iovance.com\u00a0<br \/>650-260-7120\u00a0ext. 150<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2FlNDdlMTgtMzU3OC00YmY3LWIwZTctNmMxZWUzZTE1ODBmLTEwMzA3NjktMjAyNi0xMC0yNy1lbg==\/tiny\/Iovance-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https:\/\/edge.media-server.com\/mmc\/p\/j9pwh6ke. The live and archived webcast can be accessed in the Investors section of the Company\u2019s website, IR.Iovance.com. The archived webcast will be available for one year.\u00a0 About\u00a0Iovance Biotherapeutics, Inc.\u00a0 Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013885","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https:\/\/edge.media-server.com\/mmc\/p\/j9pwh6ke. The live and archived webcast can be accessed in the Investors section of the Company\u2019s website, IR.Iovance.com. The archived webcast will be available for one year.\u00a0 About\u00a0Iovance Biotherapeutics, Inc.\u00a0 Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) &hellip; Continue reading &quot;Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T11:06:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026\",\"datePublished\":\"2026-10-27T11:06:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/\"},\"wordCount\":620,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/\",\"name\":\"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=\",\"datePublished\":\"2026-10-27T11:06:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/","og_locale":"en_US","og_type":"article","og_title":"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 - Market Newsdesk","og_description":"PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https:\/\/edge.media-server.com\/mmc\/p\/j9pwh6ke. The live and archived webcast can be accessed in the Investors section of the Company\u2019s website, IR.Iovance.com. The archived webcast will be available for one year.\u00a0 About\u00a0Iovance Biotherapeutics, Inc.\u00a0 Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) &hellip; Continue reading \"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T11:06:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026","datePublished":"2026-10-27T11:06:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/"},"wordCount":620,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/","name":"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=","datePublished":"2026-10-27T11:06:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzU0MiM3OTE3Mzk1IzIwMTkxOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-report-third-quarter-2026-financial-results-and-corporate-updates-on-thursday-november-5-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013885"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}